There are 2 types of possible underlying mechanisms how the alterations in these genes can affect clinical outcomes of BV plus chemotherapy: firstly, the alterations are associated with HIF-VEGF-VEGFR pathway and affect the efficacy of BV[17]; secondly, these genes are prognostic factor of OC and may have no relationship with BV. This evidence concerns the gene VEGFA and bacterial vaginosis.